Europa Trial
Home
Sitemap
General Public Heathcare Professionals Virtual Press Office

New Indication in CAD

EUROPA calendar
ACC 2006 - Posters
ESC 2005 - Symposium
ESC 2005 - Oral sessions
ESC 2005 - Posters
AHA 2004 - Oral Session
ESC 2004 - Hotline
ESC 2004 - Symposium
ACC 2004
ESC 2003


EUROPA study
EUROPA Results
ESC 2003 Hotline - video
Rationale for EUROPA
Rationale for Perindopril
Design & Organisation
EUROPA investigators
EUROPA collaborating centres
EUROPA Recruitment


EUROPA Slide Set
Rationale and Design
Results
Clinical Implications


EUROPA publications


PERSUADE
PERSUADE Publications
PERSUADE Results
PERSUADE Fact Sheet


PERTINENT
PERTINENT Results
PERTINENT Fact Sheet


Background : Coronary Artery Disease
Home : Healthcare professionals : EUROPA Rationale and Design - Slides
EUROPA Rationale and Design - Slides
Download the Rationale and Design Slide Set - 828 kb

EUROPA
ACE Inhibition Trials in CAD
ACE Inhibition and CAD
Mode of Action of ACE Inhibition
ACE Activity and endothelial function
Enhanced Angiotensin II favours atherosclerosis
Enhanced Bradykinin Protects against Atherosclerosis
ACE inhibition for secondary prevention of CAD
Why perindopril for EUROPA?
Hypothesis
Perindopril: a reliable 24-h blood pressure control
Perindopril specifically Increases the ecNOS Expression in patients with CAD
Specifically increase of bradykinin
Anti-ischemic effects in CAD patients
Enhancement of fibrinolysis
Normalization of structure of resistance arteries in CAD patients
Improvement in endothelial dysfunction
Anti-atherosclerotic effect
Good tolerance even in fragile patients
Aim of the study
Study endpoints
Design
Selection criteria
Documented coronary disease
This website is intended for an international audience. Drug related information may refer to unlicensed products or uses which may not be approved in your own country and you should therefore consult your local prescribing information.
This site is published and updated by the EUROPA study investigators. Site last updated March 21st 2006
To report a suspected side-effect with a Servier drug, please click here.
Terms of use - ©2005 EUROPA All rights reserved